Advertisement

Pediatric Nephrology

, Volume 29, Issue 10, pp 2055–2059 | Cite as

Eculizumab in dense-deposit disease after renal transplantation

  • Ana Sánchez-MorenoEmail author
  • Francisco De la Cerda
  • Rocío Cabrera
  • Julia Fijo
  • Margarita López-Trascasa
  • Rafael Bedoya
  • Santiago Rodríguez de Córdoba
  • Patricia Ybot-González
Brief Report

Abstract

Background

Dense-deposit disease (DDD) is a rare glomerulopathy characterized by electron-dense deposits in the glomerular basement membrane. About 50 % of patients with DDD progress to end-stage kidney disease and require dialysis within 10 years of diagnosis, and the disease often recurs after renal transplantation.

Case-Diagnosis/Treatment

We describe a 14-year-old girl with recurrent DDD in her transplanted kidney. Clinical onset was at 8 years of age, when steroid-resistant nephrotic syndrome was diagnosed with microhematuria, severe hypocomplementemia and normal kidney function. Although remission was initially observed after several plasma exchanges, nephrotic proteinuria returned and kidney function further declined 1 year later. The patient received a living-related kidney transplant. Initial allograft function was good, but proteinuria reappeared 3 months after transplantation, accompanied by a slight deterioration in kidney function. After histological confirmation of DDD recurrence and subsequent management with plasmapheresis, the patient was treated for 30 months with eculizumab, a humanized monoclonal antibody that binds to C5 complement protein. This intervention proved effective and resulted in complement inhibition, sustained remission of proteinuria and preservation of renal function. A graft biopsy 6 months later showed no progression of the renal lesions.

Conclusions

Early clinical and histological recurrence of DDD in the transplanted kidney in this 14-year-old patient was treated for 30 months with eculizumab. The patient remains asymptomatic, has no proteinuria and her kidney function is intact.

Keywords

Dense-deposit disease Eculizumab Pediatric renal transplant 

Notes

Acknowledgments

We thank M. José Viera and Flora López for their help with nursing care, and K. Shashok for improving the use of English in the manuscript (with support from the FISEVI Foundation). Medical editing was provided by Bioscript Medical Ltd, supported by Alexion Pharmaceuticals, Inc.

Conflict of interest

None.

References

  1. 1.
    Smith RJ, Alexander J, Barlow PN, Botto M, Cassavant TL, Cook HT, de Córdoba SR, Hageman GS, Jokiranta TS, Kimberling WJ, Lambris JD, Lanning LD, Levidiotis V, Licht C, Lutz HU, Meri S, Pickering MC, Quigg RJ, Rops AL, Salant DJ, Sethi S, Thurman JM, Tully HF, Tully SP, van der Vlag J, Walker PD, Würzner R, Zipfel PF; Dense Deposit Disease Focus Group (2007) New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 18:2447–2456PubMedCrossRefGoogle Scholar
  2. 2.
    Sethi S, Nester CM, Smith RJ (2012) Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int 81:434–441PubMedCrossRefGoogle Scholar
  3. 3.
    Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, Lambris JD, Lanning L, Lutz HU, Meri S, Rose NR, Salant DJ, Sethi S, Smith RJ, Smoyer W, Tully HF, Tully SP, Walker P, Welsh M, Würzner R, Zipfel PF (2005) Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 16:1392–1403PubMedCrossRefGoogle Scholar
  4. 4.
    Andrésdóttir MB (2008) Recommendations for the diagnosis and treatment of dense deposit disease. Nat Clin Pract Nephrol 4:68–69PubMedCrossRefGoogle Scholar
  5. 5.
    Lu DF, Moon M, Lanning LD, McCarthy AM, Smith RJ (2012) Clinical features and outcomes of 98 children and adults with dense deposit disease. Pediatr Nephrol 27:773–781PubMedCrossRefGoogle Scholar
  6. 6.
    Herlitz LC, Bomback AS, Markowitz GS, Stokes MB, Smith RN, Colvin RB, Appel GB, D’Agati VD (2012) Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol 23(7):1229–1237PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Smith RJ, Harris CL, Pickering MC (2011) Dense deposit disease. Mol Immunol 48:1604–1610PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    McCaughan JA, O’Rourke DM, Courtney AE (2012) Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 12:1046–1051PubMedCrossRefGoogle Scholar
  9. 9.
    Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D’Agati VD, Canetta PA, Radhakrishnan J, Appel GB (2012) Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 7:748–756PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Vivarelli M, Pasini A, Emma F (2012) Eculizumab for the treatment of dense-deposit disease. N Engl J Med 366:1163–1165PubMedCrossRefGoogle Scholar
  11. 11.
    Daina E, Noris M, Remuzzi G (2012) Eculizumab in a patient with dense-deposit disease. N Engl J Med 366:1161–1163PubMedCrossRefGoogle Scholar
  12. 12.
    Radhakrishnan S, Lunn A, Kirschfink M, Thorner P, Hebert D, Langlois V, Pluthero F, Licht C (2012) Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 366:1165–1166PubMedCrossRefGoogle Scholar
  13. 13.
    Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8:643–657Google Scholar
  14. 14.
    Gurkan S, Fyfe B, Weiss L, Xiao X, Zhang Y, Smith RJ (2013) Eculizumab and recurrent C3 glomerulonephritis. Pediatr Nephrol 28(10):1975–1981PubMedCrossRefGoogle Scholar
  15. 15.
    Pickering MC, D’Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Frémeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodríguez de Córdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT (2013) C3 glomerulopathy: consensus report. Kidney Int 84(6):1079–1089PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© IPNA 2014

Authors and Affiliations

  • Ana Sánchez-Moreno
    • 1
    Email author
  • Francisco De la Cerda
    • 1
  • Rocío Cabrera
    • 2
  • Julia Fijo
    • 1
  • Margarita López-Trascasa
    • 3
  • Rafael Bedoya
    • 1
  • Santiago Rodríguez de Córdoba
    • 4
  • Patricia Ybot-González
    • 5
  1. 1.Pediatric Nephrology UnitHospital Universitario Virgen del RocíoSevilleSpain
  2. 2.Department of PathologyHospital Universitario Virgen del RocíoSevilleSpain
  3. 3.Unidad de Inmunología, Hospital Universitario La PazCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER)MadridSpain
  4. 4.Centro de Investigación Biológica, Consejo Superior de Investigaciones Científicas (CSIC)MadridSpain
  5. 5.Neurodevelopment Unit, Department of Pediatrics, Hospital Universitario Virgen del RocíoInstituto de Biomedicina de Sevilla (IBIS)SevilleSpain

Personalised recommendations